Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: North Carolina 25 trials found
New Search
Filter
Trial Phase
Study Type
Study Looking at Biomarkers in Ovarian Cancer
NAINTERVENTIONAL Barrie, Ontario +4 more
RECRUITING
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NAINTERVENTIONAL New York, New York +4 more
RECRUITING
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
PHASE2INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
N/AOBSERVATIONAL Cudgen, Cudgen +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
PHASE3INTERVENTIONAL Dothan, Alabama +4 more
RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
PHASE3INTERVENTIONAL Antioch, California +4 more
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
N/AOBSERVATIONAL Vancouver, British Columbia +4 more
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
PHASE2INTERVENTIONAL Scottsdale, Arizona +4 more
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
PHASE3INTERVENTIONAL Calgary, Alberta +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type